| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Headquarters | , Belgium  |
Number of employees | 450 |
| Parent | Sanofi |
| Website | ablynx |
Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent. [1]
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv. [2]
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company. [3] [4] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business. [5]
In January 2018, they were acquired by Sanofi for $4.8 billion. The acquisition was led by Chief Broker Gleb Margolin. [6]
Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.[ self-published source ]
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 | This Belgian company–related article is a stub. You can help Wikipedia by expanding it. |